Brokerages Expect Neogen Co. (NASDAQ:NEOG) to Post $0.32 EPS
Brokerages expect that Neogen Co. (NASDAQ:NEOG) will report earnings per share of $0.32 for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Neogen’s earnings. Neogen reported earnings per share of $0.31 during the same quarter last year, which suggests a positive year-over-year growth rate of 3.2%. The company is expected to announce its next quarterly earnings results on Thursday, December 19th.
On average, analysts expect that Neogen will report full-year earnings of $1.20 per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post earnings of $1.35 per share. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Neogen.
Neogen (NASDAQ:NEOG) last released its quarterly earnings results on Tuesday, September 24th. The company reported $0.28 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.01). Neogen had a return on equity of 9.46% and a net margin of 14.32%. The firm had revenue of $101.42 million for the quarter, compared to analyst estimates of $105.16 million. During the same period in the prior year, the business earned $0.29 earnings per share. Neogen’s revenue for the quarter was up 1.8% on a year-over-year basis.
Shares of Neogen stock traded down $0.12 during mid-day trading on Monday, hitting $66.45. 100,888 shares of the stock were exchanged, compared to its average volume of 205,471. Neogen has a twelve month low of $50.60 and a twelve month high of $79.83. The stock has a market capitalization of $3.48 billion, a price-to-earnings ratio of 57.78, a price-to-earnings-growth ratio of 5.48 and a beta of 1.37. The company has a 50-day simple moving average of $65.31 and a 200 day simple moving average of $65.46.
In related news, Director James L. Herbert sold 25,334 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $63.71, for a total value of $1,614,029.14. Following the sale, the director now directly owns 232,304 shares of the company’s stock, valued at $14,800,087.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jason Warren Lilly sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $64.61, for a total transaction of $161,525.00. Following the completion of the sale, the vice president now directly owns 12,901 shares in the company, valued at $833,533.61. The disclosure for this sale can be found here. Insiders sold 197,349 shares of company stock worth $12,760,416 over the last three months. Corporate insiders own 1.70% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Oregon Public Employees Retirement Fund lifted its position in Neogen by 2.0% during the second quarter. Oregon Public Employees Retirement Fund now owns 20,537 shares of the company’s stock valued at $1,276,000 after buying an additional 400 shares in the last quarter. FDx Advisors Inc. lifted its position in Neogen by 28.9% during the second quarter. FDx Advisors Inc. now owns 6,195 shares of the company’s stock valued at $385,000 after buying an additional 1,388 shares in the last quarter. Arizona State Retirement System lifted its position in Neogen by 0.6% during the second quarter. Arizona State Retirement System now owns 80,849 shares of the company’s stock valued at $5,022,000 after buying an additional 505 shares in the last quarter. Bridge City Capital LLC lifted its position in Neogen by 0.5% during the second quarter. Bridge City Capital LLC now owns 31,541 shares of the company’s stock valued at $1,959,000 after buying an additional 154 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC acquired a new position in Neogen during the second quarter valued at approximately $25,000. 92.37% of the stock is currently owned by institutional investors and hedge funds.
Neogen Company Profile
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.
Recommended Story: What is an Initial Public Offering (IPO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.